HCV positive donor kidney transplant to HCV positive recipient

Transplantation of kidneys from HCV-positive donors into HCV-positive recipients is a disputed but increasingly evidence-supported response to the shortage of deceased-donor kidneys. The strategy accepts a managed risk of HCV transmission in patients who already carry the infection, potentially reducing time on dialysis and allowing organs that might otherwise be discarded to provide a functioning graft. Its safest form is restricted to candidates with detectable HCV RNA who have consented in advance, with further improvement expected from matching donor and recipient viral genotypes.

Definition and Clinical Rationale

The practice concerns kidneys recovered from donors with positive HCV serology, including donors who are HCV RNA-positive, and their transplantation into recipients who are already HCV-seropositive. It emerged within a broader shortage in which demand for transplantation greatly exceeds the supply of donated kidneys. At the end of 2009, 63,000 people were on an organ waiting list in the European Union while only 28,000 transplant procedures were performed during that year; in the United States, almost 111,000 people were listed in May 2011, with approximately 28,000 transplant procedures performed annually. In that setting, refusing every HCV-positive kidney can mean discarding a usable organ while an HCV-infected patient remains on dialysis.

The recipient category must nevertheless be defined more precisely than antibody status alone. Anti-HCV antibodies do not confer immunity and do not establish active viremia; chronic infection requires both anti-HCV antibodies and HCV RNA in serum. Consequently, an HCV-seropositive recipient may still be RNA-negative and vulnerable to transmission or infection with another viral strain. This distinction transformed the procedure from a broad serology-based policy into a narrower strategy centered on demonstrable active infection.

Transmission Risk and Early Experience

Kidney transplantation can transmit HCV. Early reports after the description of HCV in 1989 found transmission probabilities ranging from 14% to 100%, with substantial variation in the clinical consequences. In one series, half of the recipients who acquired HCV through transplantation developed criteria for chronic liver disease, whereas chronic liver disease was otherwise infrequent in the experience of another center. The heterogeneity was plausibly related to viral load in the organ, the infectivity of the strain, the volume of preservation solution, the preservation method, whether static storage or pulsatile perfusion was used, and the diagnostic tests applied.

A general consensus therefore developed against placing kidneys from HCV-positive donors into recipients with negative HCV serology. The question was more difficult for HCV-seropositive recipients: pre-existing infection might reduce the practical significance of transmission, but it could not guarantee protection. Superinfection with a different HCV genotype remained possible, and antibody positivity did not indicate that the recipient was actively viremic. The shortage of organs, especially in regions with high HCV prevalence among donors and potential recipients, kept the question open rather than permitting universal rejection of these kidneys.

In March 1990, two Spanish kidney transplant units began a pilot program using kidneys from HCV-positive donors in HCV-seropositive recipients. The initial short-term results were reassuring. Graft and patient survival among HCV-seropositive recipients were similar whether the donor had positive or negative HCV serology, and comparable proportions developed biochemical evidence of chronic liver disease, defined as alanine aminotransferase levels exceeding 2.5 times the upper normal limit for more than six consecutive months.

The apparent safety did not mean that transmission had been eliminated. When donor and recipient samples were later examined by polymerase chain reaction, five recipients who had been HCV RNA-negative were found to have received kidneys from donors who were HCV RNA-positive. Four became HCV RNA-positive after transplantation, and two developed chronic liver disease. In March 1993, the Spanish groups consequently changed their policy, limiting HCV-positive donor kidneys to waiting-list patients who already had positive HCV RNA before transplantation.

Outcomes, Waiting Time, and Uncertainty

Later single-center experiences using the same principle generally reported similar short-term outcomes when HCV-seropositive recipients received kidneys from HCV-positive rather than HCV-negative donors. Several series identified a practical benefit that was not merely statistical: recipients of HCV-positive kidneys spent significantly less time on the waiting list. For a patient exposed to the cumulative burdens of end-stage renal disease and dialysis, the shorter wait could be the central benefit of accepting a controlled infectious risk.

Registry evidence was less uniform. Analyses of the United States Renal Data System described lower patient survival after transplantation from HCV-positive donors than from HCV-negative donors, regardless of the recipient's HCV serology; the difference became apparent approximately two years after transplantation. A higher incidence of post-transplant diabetes mellitus among recipients of HCV-positive kidneys was proposed as an intermediate complication that might explain the later increase in mortality. These findings led to a demand for caution and for complete disclosure to potential recipients rather than an unconditional endorsement of the practice.

The broader clinical context also complicates assessment of benefit. HCV-related liver disease is often asymptomatic in patients receiving long-term dialysis, while fatigue, cognitive impairment, anemia, and other symptoms can arise from dialysis itself or from its many comorbidities. HCV infection has been associated with impaired mental quality of life in dialysis patients: in a study of 165 patients, 83 were anti-HCV-positive and had an independently lower mental component score on the SF-36, although no association with the physical component score was found. Treatment toxicity creates another competing risk. Interferon-based therapy can produce flu-like symptoms, anemia, neutropenia, depression, and anxiety; dose reduction occurs in roughly 35–42% of treated patients and discontinuation in about 30%.

Selection, Consent, and Policy

Current recommendations restrict HCV-positive kidneys to candidates on the waiting list who have positive HCV RNA and have consented beforehand to receive such an organ. The consent requirement recognizes that the procedure is not simply a laboratory matching exercise: the candidate must understand the possibility of transmission, the uncertainty surrounding long-term outcomes, and alternatives such as remaining on dialysis or pursuing antiviral treatment.

Antiviral treatment before transplantation may be desirable when it can achieve sustained virologic response, but it is not universally feasible. Therapy may be prolonged, expensive, toxic, and unsuccessful; patients may decline it, withdraw from it, or fail to respond, and they may be excluded from the waiting list during treatment. Although the benefits of pretransplant interferon treatment for graft and patient survival had not been proven, treatment might reduce post-transplant HCV-related glomerulonephritis and, in one report involving 50 HCV RNA-positive patients, reduced the incidence of chronic allograft nephropathy. For those unable or unwilling to undergo effective treatment, transplantation with an HCV-positive kidney may still offer a more favorable course than continued dialysis and may shorten the wait.

The procedure must be distinguished from the management of HCV-infected kidney transplant candidates more generally. All candidates should be screened for HCV and evaluated for active viremia and liver injury. Among candidates with active HCV infection, liver biopsy has remained the gold standard for staging disease, even though noninvasive approaches are being sought. Studies have found advanced liver injury or cirrhosis in 10–25% of candidates biopsied during pretransplant evaluation. Established or decompensated cirrhosis warrants referral for consideration of simultaneous liver-kidney transplantation rather than kidney-alone transplantation.

Waiting-list surveillance is essential because waiting times in some United States regions approach five to seven years. Patients not previously tested should undergo antibody screening with nucleic acid confirmation in low-prevalence regions, or direct nucleic acid testing in high-prevalence settings. A positive nucleic acid test should place the patient on hold status pending hepatology evaluation and possible treatment. Patients with a prior sustained virologic response should have annual nucleic acid testing to confirm durability; those who relapse should be placed on hold and considered for retreatment. Patients who remain viremic require annual assessment of liver disease. In one repeat-biopsy group, 8 of 13 patients, or 62%, worsened while waiting, compared with 7 of 31, or 23%, whose follow-up biopsies were obtained after transplantation. Candidates with Metavir stage 1 or 2 fibrosis were advised to undergo repeat biopsy every five years, those with stage 3 fibrosis every three years, and those progressing to early or established cirrhosis should be removed from the kidney list and referred for liver-team assessment.

Long-Term Significance and Remaining Safeguards

The accumulated center-based evidence supports the use of HCV-positive kidneys in appropriately selected HCV RNA-positive recipients as a generally safe long-term approach, with favorable graft survival, patient survival, and HCV-related liver outcomes reported in those series. The strategy also addresses an institutional paradox: organs become more likely to be discarded precisely because centers differ widely in their willingness to accept them. One analysis found that HCV-positive kidneys were 2.60 times more likely to be discarded than HCV-negative kidneys.

The principal safeguards are therefore technical, clinical, and organizational. Donor and recipient should ideally be matched by HCV genotype to reduce the possibility of superinfection with a distinct strain. Candidates should receive full information and consent before an organ becomes available. Active infection, rather than antibody positivity alone, should define eligibility. Liver disease should be staged and followed throughout the waiting period, and patients with advanced or decompensated cirrhosis should be redirected toward liver-kidney evaluation.

The decisive issue is not whether these kidneys carry risk; they do. It is whether that risk can be made proportionate to the hazards of prolonged dialysis and organ scarcity. The evidence presented supports carefully organized, preemptive transplantation for HCV RNA-positive recipients who accept HCV-positive kidneys, particularly when they are unlikely to benefit from or tolerate antiviral therapy. Broader use would require cooperation across centers and transplant systems so that suitable recipients can be identified before organs are lost. In this form, the practice converts an infectious liability into a conditional resource without erasing the need for surveillance, transparency, and clinical restraint.